Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | PHASE2 | ACTIVE NOT_RECRUITING | 2 | — | — | Apr 12, 2019 | Sep 1, 2024 | Sep 28, 2023 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| Treatment (CPX-351, enasidenib mesylate) | EXPERIMENTAL | See detailed description |
| Name | Type | Description |
|---|---|---|
| Enasidenib Mesylate | DRUG | Given PO |
| Liposome-encapsulated Daunorubicin-Cytarabine | DRUG | Given IV |
Inclusion Criteria: * Bone marrow blasts \>= 5% that develops after CR/CRi in patient with prior history of AML, no restriction on prior number of relapses or regimens * AML characterized by the IDH2 gene mutation, without requirement for a particular allelic frequency * Patients previously treated...